• Directed patient- and society-focused engagement strategies with multilaterals and regional health agencies (WHO, UNICEF, Africa CDC, Gavi, CEPI), aligning advocacy with business objectives in vaccines, MedTech, and vision.
• Conceived and led J&J's first proactive Ebola vaccination roundtable with Ministers of Health and global partners, fostering global collaboraton to accelerate patient protection.
• Built cross-functional advocacy strategies to secure multilateral financing, WHO emergency stockpile support, and country inclusion for priority products.
• Forged new partnerships across the eye health ecosystem, scaling access to cataract surgery and vision screening programs, improving health literacy and patient outcomes.

• Successfully launched SHINGRIX, GSK's blockbuster herpes zoster vaccine, in 2017. Conducted global policy landscape, built global Government Affairs strategy, created a comprehensive toolkit for launch markets, launched GA strategy in China, and led external engagement with global/regional stakeholders to strengthen infrastructure to expand access
• Served as an integral member of the Vaccines Leadership Team Adult Immunization workstream, which provided strategic recommendations to Leadership of where to invest GSK's future efforts
• Translated commercial strategy for GSK's second highest grossing vaccine, BEXSERO, into political and stakeholder engagement plans. Created a comprehensive set of resources for local teams to communicate value of Men B vaccination with policymakers, governments, medical associations, and patient advocacy organizations.
Collaborated with global stakeholders (e.g. WHO, Gavi, Gates, MRF) to develop a global roadmap to defeat meningitis by 2030
• Partnered with Johns Hopkins University to develop and conduct a 34-country adult immunization landscape analysis of government vaccine decision making and implementation. Study results published and presented to global stakeholders, also serving as evidence-based public health data to guide launch sequence and maximize adult immunization access and uptake.
• Served as Chair of IFPMA's Life-course Immunization working group, an industry association sub-team focused on building global awareness and ad

• Guided vaccine policy strategies in Eastern Europe, Middle East, and Africa, doubling vaccine business growth.
• Built innovative public-private partnerships with governments, NITAGs, First Ladies, and NGOs to expand vaccine access for women's health, pediatrics, and adolescents.
• Counseled country teams on policy environments, political dynamics, and stakeholder engagement, securing calendar inclusions and reimbursement decisions.

• Recognized by leadership for successfully broadening adult immunization policies including expanding pharmacists' authority to vaccinate, increasing adult immunization budgets, expansion of Medicaid for ZOSTAVAX and increasing dedicated adult immunization coordinators in states
• Drove business objectives by successfully increasing state general funds (~$45M from
● for immunization and ADAP, supporting vaccine requirements, expanding vaccine access including pharmacy segment ($20M+ revenue increase in 2012), protecting company from anti-vaccine legislation, and negotiating Medicaid coverage for GARDASIL and ZOSTAVAX
• Advised internal leadership (Sales, Marketing, Market Access, Govt. Affairs) on policy issues, threats/opportunities, stakeholder positions and develop timely action plans, tactics or strategies
• Special Project with MSD Japan/Vaccine Global Public Policy to inform and activate Diet members (Parliament) to strengthen central government's role in immunizations

• Contributed to the global strategic launch plan for ZOSTAVAX and GARDASIL by conducting and incorporating findings from drivers/barriers, positioning, and consumer studies in 14 international markets
• Planned, executed, and reported results from primary and secondary market research studies to support creation of short- and long-term marketing tactics and strategies
• Served on a cross-divisional team to address vaccine safety concerns by applying Merck marketing methodology to evaluate parent types, develop marketing strategies, and co authored a manuscript for submission

• Managed all day-to-day activities of the Vaccine Identification Standards Initiative (VISI), a cooperative effort to standardize vaccine packaging, labeling, and immunization record keeping
• Developed educational materials communicating benefits/risks of vaccines for professional medical and patient audiences